AR060652A1 - Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii) - Google Patents

Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii)

Info

Publication number
AR060652A1
AR060652A1 ARP070101782A ARP070101782A AR060652A1 AR 060652 A1 AR060652 A1 AR 060652A1 AR P070101782 A ARP070101782 A AR P070101782A AR P070101782 A ARP070101782 A AR P070101782A AR 060652 A1 AR060652 A1 AR 060652A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
halogen
haloalkoxy
haloalkyl
Prior art date
Application number
ARP070101782A
Other languages
English (en)
Inventor
Tomislav Stefanac
Methvin Isaac
Abdelmalik Slassi
Tao Xin
Louise Edwards
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38566746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060652(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR060652A1 publication Critical patent/AR060652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivincicacion 1: Un compuesto de formula (1) en donde R1 es metilo, halogeno o ciano; R2 es hidrogeno o fluoro; R3 es hidrogeno, fluoro o C1-3 alquilo; R4 es C1-3 alquilo o ciclopropilo; X es (2) en donde R5 es hidrogeno, C1-3 alquilo, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi o halogeno; R6 es hidrogeno, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi o halogeno; R7 es C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi o halogeno; R8 es hidrogeno, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi o halogeno; R9 es hidrogeno, fluoro o C1-3 alquilo; así como sus sales aceptables para uso farmacéutico, hidratos, isoformas, tautomeros y/o enantiomeros. Su utilizacion en terapia y composiciones farmacéuticas que los comprenden utiles para reflujo gastroesofágico, dolor, ansiedad, síndrome de intestino irritable.
ARP070101782A 2006-05-05 2007-04-25 Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii) AR060652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79766006P 2006-05-05 2006-05-05

Publications (1)

Publication Number Publication Date
AR060652A1 true AR060652A1 (es) 2008-07-02

Family

ID=38566746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101782A AR060652A1 (es) 2006-05-05 2007-04-25 Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii)

Country Status (8)

Country Link
US (1) US20070259916A1 (es)
EP (1) EP2027090A2 (es)
JP (1) JP2009536210A (es)
CN (1) CN101437798A (es)
AR (1) AR060652A1 (es)
TW (1) TW200811137A (es)
UY (1) UY30309A1 (es)
WO (1) WO2007130821A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054792A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Aminopyridine derivatives as modulators of mglur5
EA201000656A1 (ru) * 2007-10-26 2010-12-30 Астразенека Аб Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
WO2009054789A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
AU2018333913B2 (en) * 2017-09-14 2022-11-17 Daiichi Sankyo Company, Limited Compound having cyclic structure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495179A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
RU2396269C2 (ru) * 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)

Also Published As

Publication number Publication date
WO2007130821A2 (en) 2007-11-15
WO2007130821A3 (en) 2007-12-27
JP2009536210A (ja) 2009-10-08
CN101437798A (zh) 2009-05-20
UY30309A1 (es) 2007-11-30
EP2027090A2 (en) 2009-02-25
TW200811137A (en) 2008-03-01
US20070259916A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
AR060652A1 (es) Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii)
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
AR060813A1 (es) Moduladores de mglur5 iii
AR060810A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
CO6270328A2 (es) Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b
AR060651A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
RS53395B (en) DERIVATIVES N1-SULFONIL-5-FLUORPIRIMIDINONA
SE0202465D0 (sv) New compounds
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
PE20090417A1 (es) Compuestos de piperazina con accion herbicida
CO6270363A2 (es) Novedosos compuestos erivados aromaticos como inhibidores de c-fms kinase
CO6361956A2 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmaceúticas que los contienen
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR073136A1 (es) Compuestos de pirrol
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
NO20071112L (no) Nye heterosykliske karboksylsyreamidderivater
BR112015025729A2 (pt) métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal
RS53658B1 (en) 5-FLUORO-2-OXOPYRIMIDINE-1 (2H) -CARBOXYLATE DERIVATIVES AS FUNGICIDES

Legal Events

Date Code Title Description
FB Suspension of granting procedure